Pharmaceuticals News & Press Release Distribution

Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM

SHANGHAI and HONG KONG, Jan. 28, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncol...

2021-01-28 08:00 3781

Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM

SHANGHAI and HONG KONG, Jan. 28, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncol...

2021-01-28 08:00 5263

Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study

SAN DIEGO and BURLINGAME, California, Jan. 27, 2021 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, and Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical compa...

2021-01-27 20:00 5024

Sihuan Pharmaceutical (0460.HK): Xuanzhu Biopharm acquires Combio Pharmaceutical, the large-molecule integrated development platform helps drive innovation

HONG KONG, Jan. 27, 2021 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; Hong Kong Stock Exchange Stock Code: 0460) is pleased to announce its innovation Xuanzhu Biopharma...

2021-01-27 11:21 7925

Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA

INCHEON, South Korea, Jan. 26, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company's track record as a premiere CDO serv...

2021-01-27 08:26 6490

I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer

SHANGHAI, China and PLANEGG/MUNICH, Germany, Jan. 25, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), and MorphoSys (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) today announced that the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety, tolerabili...

2021-01-26 05:05 3735

BioNTech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine

MAINZ, Germany and SHANGHAI, China, 25 Jan. 2021 /PRNewswire/ -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") andShanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "Group"; Stock Code: 600196.SH, 02196.HK) today announced that according to the Food and Health Bureau of ...

2021-01-26 01:18 6405

China Biologic Announces Extraordinary General Meeting of Shareholders

BEIJING, Jan. 25, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that it has called an extraordinary general meeting of shareholders (the "EGM...

2021-01-25 21:44 9736

BioVaxys Announces Initiation Of Cancer Vaccine EU Clinical Program, Completion Of BVX-0320 Preclinical Program

VANCOUVER, BC, Jan. 25, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys" or "Company") is pleased to provide a corporate update on recent advancements of its vaccine platforms, and viral diagnostic and corporate objectives for 2021. BioVaxys is ple...

2021-01-25 21:00 3809

Boehringer Ingelheim named Top Employer in Indonesia, across Southeast Asia, and South Korea for 2021

JAKARTA, Indonesia, Jan. 25, 2021 /PRNewswire/ -- Boehringer Ingelheim has been recognized as a Top Employer for 2021 inIndonesia and six other countries across Asia - Malaysia, Philippines, Singapore, South Korea, Thailand and Vietnam - by Top Employers Institute, the global authority on excellen...

2021-01-25 10:00 2627

Boehringer Ingelheim named Top Employer in Malaysia, across Southeast Asia, and South Korea for 2021

KUALA LUMPUR, Malaysia, Jan. 25, 2021 /PRNewswire/ -- Boehringer Ingelheim has been recognized as a Top Employer for 2021 inMalaysia and six other countries acrossAsia - Indonesia, Philippines, Singapore, South Korea, Thailand and Vietnam - by Top Employers Institute, the global authority on exce...

2021-01-25 10:00 2627

Boehringer Ingelheim named Top Employer in Vietnam, across Southeast Asia, and South Korea for 2021

HO CHI MINH CITY, Vietnam, Jan. 25, 2021 /PRNewswire/ -- Boehringer Ingelheim has been recognized as a Top Employer for 2021 inVietnam and six other countries acrossAsia - Indonesia, Malaysia, Philippines, Singapore, South Korea andThailand - by Top Employers Institute, the global authority on ex...

2021-01-25 10:00 2826

Boehringer Ingelheim named Top Employer in Philippines, across Southeast Asia, and South Korea for 2021

MAKATI CITY, Philippines, Jan. 25, 2021 /PRNewswire/ -- Boehringer Ingelheim has been recognized as a Top Employer for 2021 inPhilippines and six other countries acrossAsia - Indonesia, Malaysia, Singapore, South Korea, Thailand and Vietnam - by Top Employers Institute, the global authority on ex...

2021-01-25 10:00 2352

Boehringer Ingelheim named Top Employer in Singapore, across Southeast Asia, and South Korea for 2021

SINGAPORE, Jan. 25, 2021 /PRNewswire/ -- Boehringer Ingelheim has been recognized as a Top Employer for 2021 inSingapore and six other countries across Asia - Indonesia, Malaysia, Philippines, South Korea, Thailand and Vietnam - by Top Employers Institute, the global authority on excellence in peo...

2021-01-25 10:00 2868

Boehringer Ingelheim named Top Employer in Thailand, across Southeast Asia, and South Korea for 2021

BANGKOK, Jan. 25, 2021 /PRNewswire/ -- Boehringer Ingelheim has been recognized as a Top Employer for 2021 inThailand and six other countries across Asia - Indonesia, Malaysia, Philippines, Singapore, South Korea and Vietnam - by Top Employers Institute, the global authority on excellence in peop...

2021-01-25 10:00 2374

Antengene Announces Approval of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study

SHANGHAI and HONG KONG, Jan. 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncol...

2021-01-25 08:20 3339

Nanoform's Clinical Study Indicates Positive Interim Results

HELSINKI, Jan. 22, 2021 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, today announced positive interim results from its clinical study. The faster absorption data implies that small particles can indeed be powerful. Nanoform has received...

2021-01-22 15:43 1816

Nippon Express (China) Inks MOU on Logistics Business Partnership with Jointown Pharmaceutical Group Logistics

TOKYO, Jan. 22, 2021 /PRNewswire/ -- Nippon Express (China) Co., Ltd. (hereinafter "NE China"), a subsidiary of Nippon Express Co., Ltd. of Tokyo, signed a memorandum of understanding (MOU) onDecember 18, 2020, over business partnership with Jointown Pharmaceutical Group Logistics Co., Ltd. (here...

2021-01-22 14:00 4015

Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for Patients with Severe COVID-19

TAIPEI and SAN DIEGO, Jan. 21, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that the first patient has enrolled into an investi...

2021-01-22 12:00 2201

Menarini Receives European Commission Approval of ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

- ELZONRIS is the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy, inEurope - Approval is based on the results of the largest prospective clinical trial ever conducted in patients with treatment-naïve or previously-treated BPDCN FLORENCE, Italy, Ja...

2021-01-22 02:25 4515